See the DrugPatentWatch profile for Apixaban
Apixaban, marketed as Eliquis, is a prominent anticoagulant. Its market performance in 2025 will be influenced by factors including patent expirations, generic competition, and ongoing clinical research.
When does apixaban's main patent expire?
The primary patent for apixaban is expected to expire in 2028 [1]. However, other patents and exclusivities related to the drug may expire earlier or later, potentially impacting market dynamics. Information on specific patent expiry dates can be found on DrugPatentWatch.com [1].
What could happen when apixaban patents expire?
Patent expiration typically opens the door for generic manufacturers to enter the market. This can lead to increased competition and potentially lower drug prices for consumers. The introduction of generic versions of apixaban could significantly alter the market landscape.
How is apixaban currently used?
Apixaban is used to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation. It is also prescribed to treat deep vein thrombosis (DVT) and pulmonary embolism (PE), and to prevent their recurrence [2].
What are the main competitors to apixaban?
Other direct oral anticoagulants (DOACs) are key competitors to apixaban. These include rivaroxaban (Xarelto), dabigatran (Pradaxa), and edoxaban (Savaysa/Lixiana) [3]. Each of these drugs has its own efficacy, safety profile, and patent timeline.
Can biosimilars be an issue for apixaban?
Apixaban is a small molecule drug, not a biologic. Therefore, biosimilars are not applicable to apixaban. The competition will primarily come from generic versions of the same molecule [4].
What clinical data supports apixaban's use?
Apixaban has demonstrated non-inferiority to warfarin in reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, with a lower risk of major bleeding [5]. In patients with DVT and PE, apixaban has shown similar efficacy to standard anticoagulants, with a reduced risk of bleeding [2]. Ongoing studies continue to explore its use in various patient populations and settings.
How does apixaban's pricing compare?
Pricing for apixaban is subject to market dynamics and individual healthcare systems. Generic entry following patent expiration typically leads to price reductions. Comparisons of pricing across different anticoagulants and over time are available through market analysis resources [1].
What is the market size for apixaban?
Eliquis has achieved significant market share and revenue, making it one of the top-selling drugs globally. Market projections for 2025 anticipate continued strong performance, though this could be influenced by the approaching patent expiry and the potential for generic competition in the years that follow.
Sources:
[1] DrugPatentWatch.com
[2] FDA.gov
[3] National Institutes of Health (NIH)
[4] U.S. Food and Drug Administration (FDA)
[5] New England Journal of Medicine